Voyager Therapeutics Inc. (NASDAQ:VYGR) Stock Recovers A Bit After The Big Fall
Voyager Therapeutics Inc. (NASDAQ:VYGR) jumped 5%, but the stock is down 22% in a week. Recently the company announced significant leadership changes and shift in strategy towards refocused pipeline and enhanced investment in its novel, next-gen AAV capsid platform, TRACER.
The company is optimistic that the TRACER tech platform will enable novel gene therapy candidates development for challenging severe neurological diseases that are difficult to address via conventional approaches. In addition, Voyager said that the Board chairman Michael Higgins would be interim CEO whole Glen Pierce, the board director, will become the interim Chief Scientific Officer. Higgins replaces Andre Turenne, who resigned from the company as CEO and President.
Recently the company announced that it would present preclinical findings featuring activity and durable expression of a vectorized anti-tau antibody during the 14th American Society of Gene and Cell Therapy Annual Meeting. Voyager’s SVP Neuroscience Kelly Bales said their proprietary vectorized anti-tau antibody is promising to offer more relevant therapeutic antibodies to vital brain areas related to disease progression. In the coming weeks, VYGR is a stock to watch.
Market Reaction:
On Wednesday, VYGR stock gained 5% at $3.23 with more than 124K shares, compared to its average volume of 486k shares. The stock has moved within a range of $3.1200 – 3.2400 after opening the trade at $3.21. Over the past 52-week, the stock has been trading within a range of $3.0400 – 12.6500.
